AstraZeneca’s asthma drug fails ‘smoker’s lung’ study
[ad_1] AstraZeneca said on Wednesday its asthma drug Fasenra failed to control the rate of flare-ups in patients with chronic obstructive pulmonary disease (COPD) in a late-stage study, in a setback to efforts to help tackle a severe lung disease. The drugmaker said Fasenra did not meet the primary endpoint in COPD patients compared with…